HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].

Abstract
Erlotinib is a selective epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor, which shows favorable antitumor activity against chemorefractory lung carcinoma, especially with EGFR gene mutations. We experienced a case in which oxy- genation and performance status improved in with low-dose erlotinib of 100mg/day administered every other day incidental- ly, although a dose of erlotinib 150mg/day daily is encouraged by the RECIST guideline. A 77-year-old male was diagnosed with bronchioloalveolar carcinoma(BAC)and given first-line combination chemotherapy of carboplatin and pemetrexed. However, antitumor activity was not satisfactory. His performance status(PS)was scored as 2 and home oxygen therapy (HOT)was introduced. As second-line chemotherapy, erlotinib was administered 100mg/day daily. However, the patient took the medication every other day at his own discretion, due to severe eruption and itching sensation. Since this case is classified as a nonmeasurable lesion according to the RECIST guideline, it was difficult to measure antitumor activity by tumor size. But improvement of oxygenation, with a performance status score of 0 and normalization of serum CEA level suggested that erlonitib administration of 100mg/day every other day showed antitumor activity.
AuthorsKenzo Yuyama, Hisanori Matsushita, Kenichiro Egawa, Takeshi Osawa, Yusuke Tsubouchi, Takashi Takahashi, Hirotaro Miura
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 39 Issue 3 Pg. 433-5 (Mar 2012) ISSN: 0385-0684 [Print] Japan
PMID22421774 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
Topics
  • Adenocarcinoma, Bronchiolo-Alveolar (drug therapy)
  • Aged
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms (drug therapy)
  • Male
  • Protein Kinase Inhibitors (administration & dosage, therapeutic use)
  • Quinazolines (administration & dosage, therapeutic use)
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: